.Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AX17_Evinacumab.Evinacumab

Information

Evinacumab is a fully human monoclonal antibody that inhibits angiopoietin-like protein 3 (ANGPTL3). It is indicated for use as an adjunct to other lipid-lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH). The drug has received FDA approval for this condition.

Pharmacokinetics

Pharmacokinetic parameters are based on healthy subjects and patients with HoFH after intravenous administration of evinacumab. Typical population PK data.

References

1. Bihorel, S, et al., & Harnisch, L (2025). Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia. CPT: pharmacometrics & systems pharmacology None –. DOI:10.1002/psp4.70016 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40095399

2. Bihorel, S, et al., & Harnisch, L (2025). Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia. CPT: pharmacometrics & systems pharmacology None –. DOI:10.1002/psp4.70017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40095766

Revisions

• 06/2025 initial generated model